E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mild or Moderately Active Steroid Dependent Ulcerative Colitis |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045365 |
E.1.2 | Term | Ulcerative colitis |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluation of efficacy and safety of seven Adacolumn® GMA treatment over seven consecutive weeks (1/week) in conjunction with prednisone in comparison to prednisone treatment alone for induction and maintenance of remission over a period of 24 weeks in steroid dependent Ulcerative Colitis. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- 18-75 years old - Active ulcerative colit is with documented clinical symptoms and endoscopic findings - Active disease defined as DAI (Mayo score) ≥ 4 and ≤ 10 with at least 1 point in flexible sigmoidoscopy - Steroid dependency as defined by: A. Inability to withdraw corticosteroids within three months of starting treatment, without recurrent active disease; B. Appearance of relapse within 3 months after withdrawal of corticosteroids - Colonic involvement with ulcerative colitis beyond 15cm of the anal verge - Stable doses: A. Aminosalicylates for the last 4 weeks; B. Prednisolone or equivalent dose ≤ 20 mg/day for the last 2 weeks; C. Azathioprine or 6-mercaptopurine at stable dose for the last 12 weeks - Signed informed consent form - Agree to participate in the required follow-up visits - Able to complete the diary |
|
E.4 | Principal exclusion criteria |
- Febrile (≥ 38ºC) - Evidence of toxic megacolon - Anticipated need for surgery within 24 weeks - Known obstructive diseases of the gastrointestinal system - Proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis - A history of allergic reaction to heparin or heparin-induced thrombocytopenia - A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures - Requires a central venous access catheter for the apheresis treatments - Known infection with enteric pathogens, pathogenic ova or parasites, C. difficile toxin or CMV - Hypotension (systolic blood pressure < 80 mmHg and/or diastolic blood pressure < 50 mmHg) at screening visit only - Uncontrolled hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 120 mmHg) despite medical therapy - A history of myocardial infarction or unstable angina within the past 6 months - A history of coronary artery bypass grafting surgery or angioplasty within the past 6 months - Prosthetic heart valve, pacemaker or other permanent implant - Severe cardiovascular or peripheral vascular disease, severe renal disease - Liver disease defined as levels of SGOT [AST], SGTP [ALT] or alkaline phosphatase > 2.5x the upper limit of the normal range for the laboratory performing test - History of cirrhosis - Known bleeding disorder (PT or PTT > 1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for purposes other than apheresis treatment - Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis - Known infection with Hepatitis B or C, or HIV - Abnormal hematology parameters defined as severe anemia with hemoglobin < 8.5g/dL, white blood cell count of < 3,500/µl and a granulocyte count < 2,000/µl - Fibrinogen level > 700 mg/dl - Major surgery within the past 6 months - Infection: Active infections less than 4 weeks from successful completion of antibiotic treatment for routine bacterial infection; Febrile viral infection within 4 weeks of entry into the clinical investigation; Less than 12 weeks from conclusion of therapy for systemic fungal infections - Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II) - History of dysplasia or carcinoma of the colon or lack of a complet colonoscopy in the last 12 months in patients with longstanding UC (> 10 years) - Current drug or alcohol abuse - Pregnant, lactating or planning to become pregnant during the course of the clinical investigation - Used within the last 30 days an investigational drug, biologic or device or 5 half-lifes, if known, for any investigational drug or biologic - Received cyclosporine or tacrolimus within the last 8 weeks - Received either infliximab or adalimumab within the last 8 weeks - Received beclomethasone diproprionato (Clipper), oral budesonide, topical rectal steroids or 5-ASA within the last 2 weeks - Fulminant ulcerative colitis |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary response variable: Proportion of patients in steroid free clinical resmission defined by Mayo score ≤ 2 with no individual subscore > 1 at Week 24.
Secundary response variables: - Remission, steroid free (assessed by Mayo score) at Week 12 - Response at weeks 12 and 24 (decrease in Mayo score ≥ 3 points) - Changes in acute phase reactants at all lab analysis - Rescue therapy requirements (new courses of steroids, cyclosporine, infliximab, or surgery) during study period - Time to relapse - Clinical response according to the activity indexes Truelove & Witts, Powell Tuc, Rachmilewitz (Clinical Activity Index), Lichtiger (Modified Truelove & Witts Severity Index), Walmsley (Simple Clinical Colitis Index) - Clinical remission and response at weeks 12 and 24 analysed according to concomitant use of immunosupressants
Safety variables: - Adverse events - Vital signs - Laboratory parameters - Physical examination |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 64 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 24 |